Programmed death-1 (PD-1) inhibitory ICIs like sintilimab block the interaction between PD-1 and its ligand, programmed death-ligand 1 (PD-L1), thereby lifting the immune suppression imposed by tumor cells and activating T cell-mediated anti-tumor effects (8, 9). This evidence concerns the gene CD274 and neoplasm.